Global Markets
Direct's, 'Premenstrual Syndrome - Pipeline Review, H2 2015', provides an
overview of the Premenstrual Syndrome's therapeutic pipeline.
This report
provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the
therapeutic development for Premenstrual Syndrome and special features on
late-stage and discontinued projects.
Global Markets
Direct's report features investigational drugs from across globe covering over
20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Direct's proprietary databases,
Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party
sources, put together by Global Markets Direct's team. Drug profiles/records
featured in the report undergoes periodic updation following a stringent set of
processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking,
browser based alert-box and clinical trials registries tracking ensure that the
most recent developments are captured on a real time basis.
Browse
Detail Report With TOC @ http://www.hexareports.com/report/premenstrual-syndrome-pipeline-review-h2-2015/details
Scope
- The report provides a snapshot of the global therapeutic landscape of
Premenstrual Syndrome
- The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development
for Premenstrual Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline
projects
- A review of the Premenstrual Syndrome products under development by
companies and universities/research institutes based on information derived
from company and industry-specific sources
- Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline
projects
- Coverage of the Premenstrual Syndrome pipeline on the basis of target,
MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Table Of Content
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Premenstrual Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Premenstrual Syndrome - Overview 7
Pipeline Products for Premenstrual Syndrome - Comparative Analysis 8
Premenstrual Syndrome - Therapeutics under Development by Companies 9
Premenstrual Syndrome - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Premenstrual Syndrome - Products under Development by Companies 13
Premenstrual Syndrome - Companies Involved in Therapeutics Development 14
Azevan Pharmaceuticals, Inc. 14
DEKK-TEC, Inc. 15
M et P Pharma AG 16
Pherin Pharmaceuticals, Inc. 17
Umecrine Mood AB 18
Premenstrual Syndrome - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Request
A Sample copy of This Report @ http://www.hexareports.com/sample/46622
SOM-7400 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Phenylketonuria (PKU) - Recent Pipeline Updates 33
Phenylketonuria (PKU) - Dormant Projects 36
Phenylketonuria (PKU) - Dormant Projects 36
Phenylketonuria (PKU) - Product Development Milestones 37
Featured News & Press Releases 37
May 22, 2015: Merck Serono Announces CHMP Positive Opinion to Extend
Kuvan Use to Children with PKU Below 4 Years of Age 37
Mar 30, 2015: BioMarin Announces One Oral and 7 Poster Presentations at
the 2015 American College of Medical Genetics and Genomics Annual Clinical
Genetics Meeting 37
Sep 24, 2014: FDA Receives Paragraph IV Notice Letter for KUVAN
(sapropterin dihydrochloride) Tablets 40
Sep 03, 2014: Merck Announces Detailed 26-Week Results from Phase IIIb
Study with Kuvan in Children with PKU Below 4 Years of Age 40
Apr 14, 2014: FDA Extends Market Exclusivity Six Months for BioMarin's
Rare Disease Therapy KUVAN (sapropterin dihydrochloride) Powder for Oral
Solution and Tablets 41
Jun 05, 2013: BioMarin Initiates Phase III Trial For PEG-PAL For
Treatment Of Phenylketonuria 42
Feb 19, 2013: BioMarin Announces Kuvan Significantly Improves
Inattentiveness In Phenylketonuria Patients 43
Sep 26, 2012: BioMarin Pharma To Initiate Phase III Program For PEG-PAL
In Second Quarter Of 2013 43
Jun 30, 2011: Merck Serono Initiates Phase IIIb European Study SPARK In
Children Younger Than Four Years, Suffering From Phenylketonuria 45
Mar 18, 2011: BioMarin Announces Preliminary Results From ADAPT Study 45
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Browse
Full Report @ http://www.hexareports.com/report/premenstrual-syndrome-pipeline-review-h2-2015/details
About
Us:
Hexa Reports is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact
Information:
Ryan
Shaw
Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number
1-800-489-3075
Email Us: sales@hexareports.com
Our Website: http://www.hexareports.com/
No comments:
Post a Comment